These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1064 related articles for article (PubMed ID: 23154767)

  • 21. Endometrial giant cell carcinoma: a case series and review of the spectrum of endometrial neoplasms containing giant cells.
    Mulligan AM; Plotkin A; Rouzbahman M; Soslow RA; Gilks CB; Clarke BA
    Am J Surg Pathol; 2010 Aug; 34(8):1132-8. PubMed ID: 20588176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
    McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
    Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Dualistic model of molecular pathogenesis in endometrial carcinoma].
    Lax SF
    Zentralbl Gynakol; 2002 Jan; 124(1):10-6. PubMed ID: 11873308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma.
    Hu S; Hinson JL; Matnani R; Cibull ML; Karabakhtsian RG
    Mod Pathol; 2018 Feb; 31(2):358-364. PubMed ID: 28984301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
    Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Precursors of endometrial clear cell carcinoma.
    Fadare O; Liang SX; Ulukus EC; Chambers SK; Zheng W
    Am J Surg Pathol; 2006 Dec; 30(12):1519-30. PubMed ID: 17122507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
    Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
    Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium.
    Kokawa K; Shikone T; Otani T; Nishiyama R; Ishii Y; Yagi S; Yamoto M
    Gynecol Oncol; 2001 May; 81(2):178-83. PubMed ID: 11330946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma.
    Fukuda K; Mori M; Uchiyama M; Iwai K; Iwasaka T; Sugimori H
    Gynecol Oncol; 1998 Jun; 69(3):220-5. PubMed ID: 9648591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mathematical evaluation of prognostic significance of clinico-morphological and immunohistochemical features of endometrioid adenocarcinoma].
    Razorenova TS; Samsonova EA; Pozharisskiĭ KM; Razorenov GI
    Vopr Onkol; 2007; 53(6):682-9. PubMed ID: 18416138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
    Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
    Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
    Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
    Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
    Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
    Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis.
    Demopoulos RI; Mesia AF; Mittal K; Vamvakas E
    Int J Gynecol Pathol; 1999 Jul; 18(3):233-7. PubMed ID: 12092593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
    Lax SF; Pizer ES; Ronnett BM; Kurman RJ
    Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis.
    McCluggage WG; Connolly LE; McBride HA; Kalloger S; Gilks CB
    Histopathology; 2012 Mar; 60(4):547-53. PubMed ID: 22250726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A proposed model for endometrial serous carcinogenesis.
    Zheng W; Xiang L; Fadare O; Kong B
    Am J Surg Pathol; 2011 Jan; 35(1):e1-e14. PubMed ID: 21164282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
    Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
    Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Undifferentiated Carcinoma of the Endometrium: An Expanded Immunohistochemical Analysis Including PAX-8 and Basal-Like Carcinoma Surrogate Markers.
    Ramalingam P; Masand RP; Euscher ED; Malpica A
    Int J Gynecol Pathol; 2016 Sep; 35(5):410-8. PubMed ID: 26598976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.